Insulin Glulisine Recombinant Patent Expiration
Insulin Glulisine Recombinant is Used for improving glycemic control in diabetes mellitus patients. It was first introduced by Sanofi Aventis Us Llc
Insulin Glulisine Recombinant Patents
Given below is the list of patents protecting Insulin Glulisine Recombinant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Apidra Solostar | US9717852 | Cartridge holder and pen-type injector | Apr 08, 2033 | Sanofi Aventis Us |
| Apidra Solostar | US7918833 | Pen-type injector | Sep 23, 2027 | Sanofi Aventis Us |
| Apidra Solostar | US8679069 | Pen-type injector | Apr 12, 2025 | Sanofi Aventis Us |
| Apidra Solostar | US8512297 | Pen-type injector |
Sep 15, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9561331 | Drive mechanisms suitable for use in drug delivery devices |
Aug 28, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug 19, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9533105 | Drive mechanisms suitable for use in drug delivery devices |
Aug 17, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9604009 | Drive mechanisms suitable for use in drug delivery devices |
Aug 16, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US8992486 | Pen-type injector |
Jun 05, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9011391 | Pen-type injector |
Mar 26, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US8556864 | Drive mechanisms suitable for use in drug delivery devices |
Mar 03, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US8603044 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9233211 | Relating to a pen-type injector |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9408979 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9526844 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9604008 | Drive mechanisms suitable for use in drug delivery devices |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9610409 | Drive mechanisms suitable for use in drug delivery devices |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9775954 | Pen-type injector |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US9827379 | Drive mechanisms suitable for use in drug delivery devices |
Mar 02, 2024
(Expired) | Sanofi Aventis Us |
| Apidra | US6960561 | Zinc-free and low-zinc insulin preparations having improved stability |
Jan 25, 2023
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US6960561 | Zinc-free and low-zinc insulin preparations having improved stability |
Jan 25, 2023
(Expired) | Sanofi Aventis Us |
| Apidra | US7452860 | Zinc-free and low-zinc insulin preparations having improved stability |
Mar 22, 2022
(Expired) | Sanofi Aventis Us |
| Apidra | US7696162 | Zinc-free and low-zinc insulin preparations having improved stability |
Mar 22, 2022
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US7452860 | Zinc-free and low-zinc insulin preparations having improved stability |
Mar 22, 2022
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US7696162 | Zinc-free and low-zinc insulin preparations having improved stability |
Mar 22, 2022
(Expired) | Sanofi Aventis Us |
| Apidra | US6221633 | Insulin derivatives having a rapid onset of action |
Jun 18, 2018
(Expired) | Sanofi Aventis Us |
| Apidra Solostar | US6221633 | Insulin derivatives having a rapid onset of action |
Jun 18, 2018
(Expired) | Sanofi Aventis Us |
Insulin Glulisine Recombinant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List